New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
17:41 EDTVRX, HES, WLL, WFT, BHIPoint72 Asset Management gives quarterly update on stakes
NEW STAKES: Baker Hughes (BHI), Whiting Petroleum (WLL), Valeant (VRX), Weatherford (WFT), and Hess (HES).
News For BHI;WLL;VRX;WFT;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:03 EDTBHIBaker Hughes reports U.S. rig count up 3 to 862
Subscribe for More Information
July 1, 2015
18:20 EDTWLLShell CEO says Opec production has pressured shale companies, FT reports
In an interview with the Financial Times, Shell (RDS.A, RDS.B) CEO Ben van Beurden said Opec's decision not to cut production has sent a "powerful signal... to shale oil companies as well as their financiers that they cannot forget the price risk. The industry will remember it for some time." The CEO noted that industry efforts to boost efficiency and cut costs should keep production going for "a while to come... until the sweet spots start running out." Publicly traded companies in the space include Chevron (CVX), Anadarko Petroleum (APC), Exxon Mobil (XOM), BP (BP), Marathon Oil (MRO), BHP Billiton (BHP), ConocoPhillips (COP), Pioneer Natural Resources (PXD), EOG Resources (EOG), Concho (CXO), Whiting Petroleum (WLL), and Continental Resources (CLR). Reference Link
June 26, 2015
16:16 EDTVRXOn The Fly: Top stock stories for Friday
Subscribe for More Information
13:04 EDTBHIBaker Hughes reports U.S. rig count up 2 to 859
Subscribe for More Information
09:37 EDTVRXValeant unlikely to pursue Zoetis acquisition, CNBC's Faber says
Subscribe for More Information
09:33 EDTVRXValeant made Zoetis approach as courtesy to Ackman, CNBC reports
Subscribe for More Information
09:33 EDTVRXValeant not going to pursue Zoetis acquisition, CNBC's Faber reports
06:06 EDTVRXZoetis downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:02 EDTVRXJPMorgan assumes Valeant pays $60/share for Zoetis
JPMorgan analyst Chris Schott believes Zoetis (ZTS) would bring "an attractive, durable, cash-pay business" to Valeant's portfolio should a merger occur. The Wall Street Journal last night reported that Valeant has approached Zoetis regarding a potential takeover. Schott sees the deal being minimally accretive to near-term earnings, and assumes Valeant pays $60 per share for Zoetis, or a 20% premium to Wednesday's closing price. The analyst thinks any offer would include a substantial equity component given Valeant's levered balance sheet following the Salix acquisition. Schott keeps an Overweight rating on Valeant and a Neutral rating on Zoetis.
June 25, 2015
16:13 EDTVRXValeant made preliminary takeover approach to Zoetis, WSJ reports
Valeant Pharmaceuticals (VRX) made a preliminary approach regarding a potential deal to buy Zoetis (ZTS), said The Wall Street Journal, citing people familiar with the matter. The report said it was not clear if Zoetis is open to a sale or what was the companyís reaction to the approach. Zoetis share spiked more than 11% into the close following the report and are up another 1% to $55.95 in after hours trading. Reference Link
15:58 EDTVRXZoetis jumps 11%, halted for circuit breaker after report of Valeant approach
Subscribe for More Information
15:57 EDTVRXValeant made preliminary takeover approach to Zoetis, DJ reports
Subscribe for More Information
07:35 EDTBHIBaker Hughes volatility low into Haliburtonís expected closing of purchase
Subscribe for More Information
07:08 EDTBHIHalliburton volatility low into expected closing of Baker Hughes acquisition
Subscribe for More Information
June 24, 2015
17:57 EDTBHIWall Street applauds Senate giving go-ahead for 'fast track' trade powers
Subscribe for More Information
07:19 EDTWFT, BHIU.K. panel to decide on first fracking in area since 2011, WSJ reports
Subscribe for More Information
June 23, 2015
09:20 EDTVRXValeant and Progenics announces submission of NDA to FDA for RELISTOR
Valeant Pharmaceuticals International (VRX) and Progenics Pharmaceuticals (PGNX) announced that Valeant submitted a New Drug Application, or NDA, to the FDA for RELISTOR, or methylnaltrexone bromide, Tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
07:34 EDTWLLGlobal Hunter Securities to hold a conference
Subscribe for More Information
07:25 EDTVRXPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use